The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...

So, what will the early months of 2026 look like for the biotech sector? First, let me say that the biotech sector being 'en fuego' over the past three quarters has made my year as far as my portfolio ...